Prognostic value of SS18–SSX fusion type in synovial sarcoma; systematic review and meta-analysis

SpringerPlus

Table 1 Clinical characteristics of the patients included in the meta-analysis

References	Country	Study design	Total N	Median/mean follow-up
Panagopoulos et al. (2001)	Sweden	N/D	60	35 months
Mezzelani et al. (2001)	Italy	Consecutive	72	N/D
Ladanyi et al. (2002)	USA	Retrospective	242	2·7 years
Guillou et al. (2004)	Switzerland	Retrospective	165	37 months
Takenaka et al. (2008)	Japan	Retrospective	108	54 months
ten Heuvel et al. (2009)	Netherlands	N/D	45	55 months
Sun et al. (2009)	China	N/D	141	54 months
Krieg et al. (2011)	Switzerland	Retrospective	62	11.4 years
Charbonneau et al. (2013)	USA	Retrospective	103	N/D
Ren et al. (2013)	China	Retrospective	88	42·7 months

References	Analyzed N	Fusion gene analysis	SS18–SSX1/SS18–SSX2	Survival analysis
Panagopoulos et al. (2001)	47	PCR	31/16	DSS, MFS
Mezzelani et al. (2001)	64	PCR	40/24	MFS
Ladanyi et al. (2002)	202	PCR or FISH	122/80	OS
Guillou et al. (2004)	141	PCR	99/42	DSS, MFS
Takenaka et al. (2008)	91	PCR	57/34	OS, MFS
ten Heuvel et al. (2009)	45	PCR or FISH	27/18	DSS, MFS
Sun et al. (2009)	141	PCR	50/91	DSS, MFS
Krieg et al. (2011)	43	PCR	30/13	OS
Charbonneau et al. (2013)	40	PCR	24/16	PFS
Ren et al. (2013)	88	PCR	47/41	OS

N/D not document, N number of patients, PCR reverse transcription-polymerase chain reaction, FISH fluorescent in situ hybridization, OS overall survival, DSS disease-specific survival, PFS progression-free survival, MFS metastasis-free survival.